SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Vivus: into single digits
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BDR who wrote (387)4/27/1998 11:56:00 AM
From: Don Dunlap   of 1016
 
Well, Mr. Fayemi was only 1000% off his target price. Almost 2000% excluding the recent runup. Interesting that the post says he was with Wheat First. That means three brokerages within two? years Wheat First, Genesis Merchant and now Cruttendon Roth.

Someone else asked about Caverject refills. I remember seeing somewhere that Caverject had sales of 60 million. I don't remember where. If true, we could hopefully draw a parallel in that Caverject kept a niche when Muse came on the market, and hopefully Muse will keeps its niche with Viagra on the market.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News